Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents

Summary

The MoodRing intervention is a mobile application for adolescents, parents, and an accompanying web-based clinician portal which enables adolescents to monitor their mood through the use of passively collected smartphone data. This randomized controlled trial will evaluate whether MoodRing as compared to usual care improves the quality of depression management.

Conditions

• Depression in Adolescence

Interventions

DEVICE

MoodRing App

Adolescents and parents in the MR arm will receive instructions to download the MR app and AWARE app, customize the app, utilize an app-based self-guided onboarding, and review questions with the research team. The MR app provides the adolescent and their parent a notification to view a weekly report predicting their mood score (i.e. depression severity level similar to the Patient health questionnaire-9). The MR app will provide a library of coping strategies for adolescents and opportunities to self-track their mood. Clinicians in the MR Arm will get access to a MR portal online. They will be able to view patients they are a provider for. The clinician will receive in-person and/or video-based training to use the portal.

OTHER

Usual Care

Adolescents and parents in the usual care arm will receive instructions to download the AWARE app. This app will only track data and will not be interactive. Otherwise they will receive care as per routine by their healthcare provider team.

Sponsors & Collaborators

• NuRelm, Inc.

  collaborator INDUSTRY

• National Institute of Mental Health (NIMH)

  collaborator NIH

• University of Virginia

  collaborator OTHER

• Ana Radovic

  lead OTHER

Principal Investigators

• Sam Shaaban, BSEE, MBA · NuRelm, Inc.

• Ana Radovic, MD, MSc · University of Pittsburgh

• Afsaneh Doryab, Ph.D. CS · University of Virginia

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

12 Years

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-05-12

Primary Completion

2024-03-27

Completion

2024-06-20

FDA Device

Yes

Countries

• United States

Study Locations